<DOC>
	<DOCNO>NCT00301951</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor umbilical cord blood transplant help stop growth cancer cell patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving chemotherapy , fludarabine busulfan , antithymocyte globulin transplant tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well give low-dose fludarabine busulfan together anti-thymocyte globulin , follow donor umbilical cord blood transplant work treat patient advanced hematologic cancer .</brief_summary>
	<brief_title>Low-Dose Fludarabine , Busulfan , Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant Treating Patients With Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess feasibility perform umbilical cord blood transplant old patient young infirm patient advance hematologic malignancy use reduced-intensity preparative regimen , determine &gt; 80 % engraftment rate day 180 &lt; 50 % transplant-related mortality rate day 100 . Secondary - Describe time neutrophil platelet recovery patient treat regimen . - Determine disease-specific , event-free , overall survival rate day 180 360 . - Determine incidence , severity , time acute chronic graft-versus-host disease patient treat regimen . - Evaluate T-cell , B-cell , natural killer cell recovery patient treat regimen . - Assess lineage-specific chimerism transplantation describe contribution individual cord blood unit post-transplantation hematopoiesis . OUTLINE : This pilot study . - Reduced-intensity preparative regimen : Patients receive fludarabine IV 30 minute day -8 -4 , busulfan IV 2 hour 4 time daily day -4 -3 , anti-thymocyte globulin IV 6 hour day -3 -1 . - Allogeneic umbilical cord blood transplantation : Patients undergo allogeneic umbilical cord blood transplant day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously IV begin day 7 continue blood count recover . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive tacrolimus IV continuously 24 hour orally ( tolerate ) begin day -2 continue approximately 9 month . Patients also receive oral mycophenolate mofetil twice daily day 1-50 . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow advanced hematologic malignancy : Acute myeloid leukemia ( AML ) meeting follow criterion : Considered incurable chemotherapy Marrow blast ≤ 10 % ( may achieve use standard chemotherapy regimen ) Meets follow criterion : Highrisk cytogenetics ( 7 , 7q , 5 , 5q , ( 6,9 ) , ( 9,11 ) , complex [ ≥ 3 abnormality ] , Philadelphia chromosome positive [ Ph+ ] ) AML evolve prior myelodysplasia AML secondary prior chemotherapy Failed achieve remission In second subsequent remission Refractory relapse Myelodysplastic syndrome ( MDS ) meeting follow criterion : Must highrisk feature , include follow : Intermediate2 high risk International Prognostic Scoring System ( IPSS ) score Chronic myelomonocytic leukemia Marrow blast ≤ 20 % ( chemotherapy may give achieve target blast level ) No rapidly progressive disease Acute lymphoblastic leukemia meeting follow criterion : Considered incurable chemotherapy Meets follow criterion : Highrisk cytogenetics ( Ph+ , ( 4,11 ) , 11q23 abnormality , monosomy 7 ) Required &gt; 1 induction course achieve remission Failed enter remission In second subsequent remission Marrow blast ≤ 10 % ( chemotherapy may give achieve target blast level ) Chronic myelogenous leukemia ( CML ) meet 1 follow criterion : Chronic phase CML fail imatinib mesylate therapy , define progressive disease fail achieve major cytogenetic response 1 year initiation therapy Accelerated phase CML meeting 1 follow criterion : Failed achieve complete cytogenetic remission 1 year initiation therapy Failed achieve cytogenetic response 6 month therapy Progressive disease , demonstrate worsen cytogenetic response 2 consecutive analysis separate 4 week In blast crisis &lt; 10 % blast bone marrow Multiple myeloma meeting follow criterion : Stage IIII disease Meets follow criterion : In relapse autologous transplantation Refractory ≥ 2 prior conventional myeloma therapy Chromosome 13 abnormality ( may enrol diagnosis initial progression ) Lymphoma The following subtypes eligible : Diffuse large cell Follicular large cell Mantle cell Peripheral Tcell Tnatural killer ( TNK ) cell Hodgkin 's lymphoma Must progress , recur prior therapy , fail respond primary therapy Relapsed disease autologous stem cell transplantation ( SCT ) allow Lowgrade nonHodgkin 's lymphoma meeting 1 follow criterion : Relapsed refractory disease ≥ 2 chemotherapybased treatment regimen Relapsed autologous SCT Chronic lymphocytic leukemia Relapsed refractory disease ≥ 2 chemotherapybased treatment regimen Relapsed autologous SCT Meets 1 follow criterion : Age 5570 year Under age 55 deem ineligible conventional highdose chemotherapy , indicate following : Poor cardiac function ( i.e. , LVEF &lt; 40 % ) Poor pulmonary function ( i.e. , DLCO &lt; 50 % ) Hepatic dysfunction Prior myeloablative therapy Not eligible autologous SCT conventional therapy Umbilical cord blood donor available Matched ≥ 4 6 HLA antigen ( A , B , DR ) Has 13 unit umbilical cord blood available Must HLAidentical 1 antigen mismatch related donor potential HLAmatched unrelated donor readily available NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine clearance &gt; 40 mL/min Creatinine &lt; 2.0 mg/dL AST alkaline phosphatase &lt; 3 time upper limit normal ( ULN ) Bilirubin &lt; 2.0 mg/dL Hepatitis C active hepatitis B virus ( HBV ) allow ≤ grade 2 fibrosis and/or inflammation liver biopsy Patients history HBV infection test hepatitis B epsilon ( HBe ) antigen , antiHBe , HBV DNA ( quantitative ) Patients active HBV viral replication receive antiviral therapy Ejection fraction &gt; 30 % DLCO ≥ 40 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require ongoing antibiotic treatment HIV negative PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>